This week, we welcome Dr. Amar Kishan to our show to discuss the role of radiation oncology in the management of patients with testicular cancer. As our listeners know by now, the management of patients with testicular cancer spans multiple specialities. We always appreciate hearing from our colleagues about their perspective.Episode contents:- What are important studies to send to radiation oncology prior to their appointment? - How radiation is planned for seminoma patients and a discussion of the treatment course- Implications on spermatogenesis, organ function, and infertility - Role of proton therapy?- Emerging therapies****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

The discussion dives deep into disseminated testicular cancer and its treatment options. Personal anecdotes add warmth as speakers share insights on teamwork and recent experiences. A captivating case study highlights the significance of a multidisciplinary approach. The evolution of treatment regimens showcases remarkable advancements in cure rates. Innovative strategies for relapsed or refractory disease, including high-dose carboplatin, point to the future of patient care. Tune in for engaging insights and expert analysis!

Dive deep into the world of testicular cancer as the discussion highlights the nuances of treating Stage 1 and 2 diseases. Learn about effective management strategies, including chemotherapy, radiation, and surgery. The fascinating exploration of pivotal trials illuminates how they shape current treatments. Personal anecdotes and humor make the complex subject relatable while showcasing impressive survival rates, especially for Stage 1 seminoma. It's an insightful blend of medical expertise and engaging dialogue!

Dive into the basics of testicular cancer with an exploration of germ cell tumors. Learn about key tumor markers like AFP and beta-HCG that guide diagnosis and treatment. The hosts also discuss the importance of inguinal orchiectomy for effective management. As they blend clinical insights with personal anecdotes, gain a deeper understanding of seminoma versus non-seminoma and the complexities of cancer staging. Tune in for an exciting journey into oncology with a focus on high cure rates!

The hosts dive into the complex world of relapsed and refractory acute myeloid leukemia, discussing how to define primary induction failure and exploring various treatment options. They highlight innovative strategies like FLAG and CLAG regimens to enhance cytarabine's effectiveness. The conversation also addresses the role of targeted therapies and the significance of clinical trials in improving outcomes. Personal stories add a relatable touch, making this evolving treatment landscape even more engaging.

Explore innovative treatment strategies for elderly patients with acute myeloid leukemia who can't handle intensive therapy. Learn about assessing fitness for treatment and the significance of genetic mutations. Discover how modern therapies like azacitidine and venetoclax are reshaping care for frail patients. Key clinical trials, including Viali-A and LACEWING, reveal improved outcomes. The episode delivers valuable insights into navigating the complexities of AML management in older, less fit patients.

Dr. Amar Kelkar, a hematology and oncology expert from Dana-Farber Cancer Institute, delves into allogeneic transplant options for acute myeloid leukemia (AML). He discusses the various conditioning regimens and how to choose the best one for patients. The conversation also highlights the critical role of measurable residual disease testing and maintenance therapies. Kelkar sheds light on graft-versus-host disease and recent advancements in haploidentical transplants, addressing racial disparities in transplant outcomes for better equity.

Dr. Amar Kelkar, an instructor at Harvard Medical School and specialist at Dana-Farber, joins for an enlightening dive into allogeneic transplants for AML. He unpacks key eligibility criteria for patients, stressing the importance of minimal residual disease status. The conversation also illuminates the critical role of HLA matching and donor selection factors. Additionally, Dr. Kelkar compares various stem cell sources, revealing unique insights about outcomes in haploidentical and cord blood transplants. His expert perspective makes this complex topic accessible.

This discussion highlights cutting-edge maintenance therapies for acute myeloid leukemia (AML). It reviews the role of cytarabine consolidation and the significance of hypomethylating agents in restoring gene function. Personal anecdotes enrich insights on the treatment journey of patients. Challenges surrounding targeted therapies, especially FLT3 inhibitors, are explored alongside the promising drug giltaritinib. The importance of evaluating clinical trial data to enhance patient outcomes is emphasized, making for a comprehensive overview of AML therapies.

Delve into the complexities of consolidation therapies for acute myeloid leukemia (AML). Discover the pivotal role of allogeneic stem cell transplants in improving patient outcomes. Learn about high-dose vs. lower-dose cytarabine treatments and their effects on relapse prevention. Explore the evolution of transplant techniques, including donor matching and conditioning methods. Plus, see how minimal residual disease (MRD) testing shapes treatment strategies, potentially minimizing unnecessary transplants while boosting survival rates.